HitGen has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets of interest.    Under the agreement, HitGen will use its technology platform, based on DNA-encoded library design, synthesis, and screening, to discover the leads for Boehringer Ingelheim. HitGen will receive upfront payments, and will also be eligible for milestone payments from Boehringer Ingelheim.    “This collaboration further emphasize...